34,629 Shares in ARK Genomic Revolution ETF $ARKG Bought by Hanover Advisors Inc.

Hanover Advisors Inc. purchased a new stake in shares of ARK Genomic Revolution ETF (BATS:ARKG) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 34,629 shares of the company’s stock, valued at approximately $962,000. Hanover Advisors Inc. owned 0.08% of ARK Genomic Revolution ETF as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Jaffetilchin Investment Partners LLC purchased a new stake in shares of ARK Genomic Revolution ETF during the second quarter worth about $994,000. Next Capital Management LLC bought a new position in ARK Genomic Revolution ETF during the 2nd quarter valued at approximately $318,000. D.A. Davidson & CO. purchased a new stake in ARK Genomic Revolution ETF in the 3rd quarter worth approximately $1,392,000. JPMorgan Chase & Co. grew its position in shares of ARK Genomic Revolution ETF by 26.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,353,952 shares of the company’s stock worth $106,019,000 after buying an additional 920,430 shares during the last quarter. Finally, Florin Court Capital LLP bought a new stake in shares of ARK Genomic Revolution ETF in the 3rd quarter worth approximately $880,000.

ARK Genomic Revolution ETF Stock Performance

Shares of ARK Genomic Revolution ETF stock opened at $28.36 on Friday. The business has a 50 day moving average of $30.46 and a 200 day moving average of $28.66. ARK Genomic Revolution ETF has a 52 week low of $17.50 and a 52 week high of $34.39.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.